1546. Update in Syphilis Proctitis: Insights from a Case Series and Literature Review
Ferzacca E, Dunne D, Barbieri A, Aoun-Barakat L. 1546. Update in Syphilis Proctitis: Insights from a Case Series and Literature Review. Open Forum Infectious Diseases 2020, 7: s772-s773. PMCID: PMC7777609, DOI: 10.1093/ofid/ofaa439.1726.Peer-Reviewed Original ResearchCases of proctitisLower gastrointestinal symptomsLymphoplasmacytic inflammatory infiltrateProminent plasma cellsInflammatory bowel diseasePhysical exam findingsMale sex assignmentPublic health consequencesAnal painAnorectal massAnorectal ulcersSyphilitic proctitisGastrointestinal symptomsChart reviewRectal massSyphilis infectionBowel diseaseRare manifestationCase seriesInflammatory infiltrateEarly syphilisExam findingsBiopsy specimensMedical recordsMisdiagnosis resultsTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes